Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Sulisobenzone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.52 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.52 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.44 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulisobenzone SCHEMBL14058252 | 1.00 | LMNA (0.97) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL3932826 | 1.00 | LMNA (0.97) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL812671 | 0.99 | MAPT (0.95) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL167868 | 0.99 | LMNA (1.00) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL16330 | 0.99 | LMNA (1.00) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL9474717 | 0.99 | LMNA (1.00) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL29360128 | 0.99 | LMNA (1.00) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL6295950 | 0.97 | LMNA (0.97) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL22712408 | 0.97 | LMNA (0.97) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL10723301 | 0.97 | LMNA (0.97) | LMNAMAPTKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107189197-B | Comprehensive conveying pipe for high-strength insulating flame-retardant pipeline gallery | 上海中塑管业有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-4482204-A | Ultraviolet absorbers in optical fiber coatings | AT&T BELL LABORATORIES (US) | 1984-11-13 | — | — | US | claimed |
| US-4087406-A | Metal salts of hindered piperidine carboxylic acids and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1978-05-02 | — | — | US | claimed |
| WO-2026100525-A1 | BLACK RESIN PARTICLE DISPERSION AND AQUEOUS INK COMPOSITION FOR WRITING IMPLEMENTS CONTAINING SAME | 三菱鉛筆株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-4692260-A1 | KIT FOR THREE-COMPONENT COATING COMPOSITION, THREE-COMPONENT COATING COMPOSITION, AND IN-MOLD COATING METHOD | Kansai Paint Co., Ltd (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021615-A1 | COATING COMPOSITION AND IN-MOLD COATING METHOD | KANSAI PAINT CO LTD (JP) | 2026-01-22 | — | — | US | disclosed |
| US-12485593-B2 | Method for forming in-mold coating multi-layer coating film | KANSAI PAINT CO., LTD. (JP) | 2025-12-02 | — | — | US | disclosed |
| US-20250291269-A1 | ELECTROSTATIC IMAGE DEVELOPING TONER, ELECTROSTATIC IMAGE DEVELOPER, TONER CARTRIDGE, PROCESS CARTRIDGE, IMAGE FORMING APPARATUS, AND IMAGE FORMING METHOD | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2025-09-18 | — | — | US | disclosed |
| US-20250230338-A1 | THERMOSETTING COATING MATERIAL COMPOSITION, COATED ARTICLE, AND IN-MOLD COATING METHOD | KANSAI PAINT CO., LTD. (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12325805-B2 | Coating composition and in-mold coating method | KANSAI PAINT CO., LTD. (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250144859-A1 | METHOD FOR FORMING IN-MOLD COATING MULTI-LAYER COATING FILM | KANSAI PAINT CO., LTD. (JP) | 2025-05-08 | — | — | US | disclosed |
| US-4017325-A | Pigment composition | HULL-SMITH CHEMICALS, INC. (US) | 1977-04-12 | — | — | US | disclosed |
| US-4001181-A | ACTINIC RADIATION STABILIZERS | CIBA-GEIGY CORPORATION (US) | 1977-01-04 | — | — | US | disclosed |
| US-3991012-A | AGAINST ULTRAVIOLET DETERIORATION OF POLYMERS | CIBA-GEIGY CORPORATION (US) | 1976-11-09 | — | — | US | disclosed |
| US-3979360-A | Compositions stabilized with benzoyloxybenzamides | CIBA-GEIGY CORPORATION (US) | 1976-09-07 | — | — | US | disclosed |
| US-3960809-A | POLYMERS | CIBA-GEIGY CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
| US-3956361-A | THERMAL AND OXIDATIVE STABILIZER FOR POLYMER | CIBA-GEIGY CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3941746-A | Containing hindered phenolic norbornane-2,3-dicarboximides stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1976-03-02 | — | — | US | disclosed |
| US-3939163-A | Metal salts of hindered piperidine carboxylic acids and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1976-02-17 | — | — | US | disclosed |
| US-3931442-A | Temporary modification of a pattern mask for use in forming a color CRT screen and a process for modifying the same | GTE SYLVANIA INCORPORATED (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021615-A1 | COATING COMPOSITION AND IN-MOLD COATING METHOD | VIM, VCL, C9 | SLC6A2 4183/4885PDE4A 4305/4885HRH1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.